NCT07113132View on ClinicalTrials.gov

Role of SF3B1 Mutation in Assessment of Acute and Chronic Lymphatic Leukemia

Not yet recruitingOBSERVATIONAL

Enrollment

84

Participants

Timeline

Start Date

August 1, 2025

Primary Completion Date

July 1, 2026

Study Completion Date

July 1, 2027

Conditions

Acute Lymphoblastic Leukemia ALLChronic Lymphocytic Leukemia (CLL)

All Listed Sponsors

lead

Safaa Ali

OTHER

NCT07113132 - Role of SF3B1 Mutation in Assessment of Acute and Chronic Lymphatic Leukemia | Biotech Hunter | Biotech Hunter